Log in | Register

Is ticagrelor safe in intensive care unit patients? Focus on bradycardic events

Xavier Valette| Suzanne Goursaud| Joachim Alexandre| Maxime Leclerc| Vincent Roule| Farzin Beygui| Damien du Cheyron
Letter
Volume 44, Issue 2 / February , 2018

Pages 270 - 271

No abstract available.

References

  1. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, PLATO Investigators, Freij A, Thorsén M (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361:1045–1057
    • View reference on publisher's website
    • View reference on PubMed
  2. Scirica BM, Cannon CP, Emanuelsson H, Michelson EL, Harrington RA, Husted S, James S, Katus H, Pais P, Raev D, Spinar J, Steg PG, Storey RF, Wallentin L, PLATO Investigators (2011) The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (platelet inhibition and patient outcomes) trial. J Am Coll Cardiol 57:1908–1916
    • View reference on publisher's website
    • View reference on PubMed
  3. Cattaneo M, Schulz R, Nylander S (2014) Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance. J Am Coll Cardiol 63:2503–2509
    • View reference on publisher's website
    • View reference on PubMed
  4. Bonello L, Laine M, Kipson N, Mancini J, Helal O, Fromonot J, Gariboldi V, Condo J, Thuny F, Frere C, Camoin-Jau L, Paganelli F, Dignat-George F, Guieu R (2014) Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome. J Am Coll Cardiol 63:872–877
    • View reference on publisher's website
    • View reference on PubMed

Sign In

Connect with ICM

Top 5 Articles Editors Picks Supplement